Bahrain successfully administers first CRISPR-based sickle cell treatment outside the US
Casgevy, developed by Vertex Pharmaceuticals and CRISPR Therapeutics, is the first licensed therapy to utilize CRISPR/Cas9 gene-editing technology.
It is designed as a potential treatment for SCD and transfusion-dependent beta-thalassemia, two inherited blood disorders that affect patients' health and life expectancy.
Bahrain approved Casgevy for use on Dec. 2, 2023, becoming the second country globally and the first in the Middle East to do so. The approval followed an assessment of the therapy's safety, quality, and effectiveness.
The treatment involves a multi-step process. Firstly, stem cells are collected from the patient's bone marrow. Then, they are genetically edited to enable the production of functional hemoglobin. Lastly, the modified cells are reinfused into the patient after thorough safety testing.
Bahrain's Minister of Health Dr. Jaleela bint Al-Sayed Jawad Hasan said the successful administration of the treatment highlighted the kingdom's commitment to integrating advanced medical innovations.
'We are delivering on our mandate to provide access to life-changing therapies for all beneficiaries and positioning Bahrain as a hub for innovative medical care, in line with the directives of King Hamad bin Isa Al-Khalifa and Crown Prince Salman bin Hamad Al-Khalifa,' she said.
Dr. Shaikh Fahad bin Khalifa bin Salman Al-Khalifa, commander of the Royal Medical Services, added: 'Bahrain is proud to be at the forefront of cutting-edge healthcare advancements in the region. This achievement provides new hope for patients with complex blood disorders and underscores Bahrain's growing role in medical innovation.'
Dr. Edward Rowland, CEO of the Bahrain Oncology Centre, described the development as a reflection of the institution's focus on advanced technology and global partnerships.
The initiative is part of Bahrain's national healthcare strategy, which prioritizes medical innovation and collaboration, and has been supported by the Ministry of Health, the Royal Medical Services, government hospitals, and the National Health Regulatory Authority.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Al Arabiya
3 days ago
- Al Arabiya
Thai Princess, in hospital since 2022, treated for blood infection: Palace
Thailand's Princess Bajrakitiyabha Narendira Debyavati developed a severe bloodstream infection and remains under medical care, the royal palace said on Friday in its first announcement about her condition since 2023. The 46-year-old princess, the oldest child of King Maha Vajiralongkorn, was hospitalized in December 2022 after losing consciousness as a result of a heart condition, the palace said in a statement. The palace said medication and equipment were being used to support her lung and kidney function. Last week, a medical team administered antibiotics after detecting a severe infection in her bloodstream. Blood pressure medication was also administered, the palace said.
Al Arabiya
29-07-2025
- Al Arabiya
Us health officials crack down on kratom-related products after complaints from supplement industry
US health officials are warning Americans about the risks of an opioid-like ingredient increasingly added to energy drinks, gummies, and supplements sold at gas stations and convenience stores, recommending a nationwide ban. The chemical known as 7-hydroxymitragynine is a component of kratom, a plant native to Southeast Asia that has gained popularity in the US as an unapproved treatment for pain, anxiety, and drug dependence. In recent months, dietary supplement companies that sell kratom have been urging the Food and Drug Administration to crack down on the products containing 7-OH, portraying them as dangerously strong synthetic versions of the original ingredient. The FDA action is not focused on natural kratom leaf products, according to a statement Tuesday by the US Department of Health and Human Services. The agency said it was releasing a report to educate about the risks of 7-OH and its distinction from the kratom plant leaf. Regulators are also recommending that the ingredient be placed on the federal government's most restrictive list of illegal drugs, which also includes LSD and heroin. '7-OH is an opioid that can be more potent than morphine,' said FDA Commissioner Marty Makary. 'We need regulation and public education to prevent another wave of the opioid epidemic.' The agency's recommendation will be reviewed by the Drug Enforcement Administration, which sets federal rules for high-risk drugs, including prescription medicines and illicit substances. Federal regulators have been scrutinizing kratom for about a decade after reports of addiction, injury, and overdose. But users and distributors have long opposed efforts to regulate it, saying kratom could be a safer alternative to opioid painkillers that sparked the ongoing drug addiction epidemic. Last month, the FDA issued warning letters to seven companies selling drinks, gummies, and powders infused with the drug. Regulators said the products violated FDA rules because they have not been evaluated for safety and, in some cases, claimed to treat medical conditions including pain, arthritis, and anxiety. Supplement executives quickly applauded the move. 'The FDA demonstrated the exact kind of data-driven proactive regulatory excellence needed to safeguard unwitting consumers across the US,' said Ryan Niddel of Diversified Botanics, a Utah-based company that sells kratom supplements. An industry group, the American Kratom Association, has lobbied Congress for years against restrictions on the plant. Legislation supported by the group would prohibit the FDA from regulating kratom more strictly than food and dietary supplements. Nearly a decade ago, the federal government came close to a national ban on the substance. In 2016, the DEA announced plans to add kratom to the government's most restrictive schedule 1 of illegal drugs. But the plan stalled after a flood of public complaints, including a letter signed by more than 60 members of Congress. The FDA then began studying the ingredient, concluding in 2018 that kratom contains many of the same chemicals as opioids, the addictive class of drugs that includes painkillers like OxyContin as well as heroin and fentanyl. Since then, FDA regulators have continued to issue warnings about cases of injury, addiction, and death with kratom supplements, which are usually sold in capsules or powders. In recent months, the FDA has also issued warnings on other unapproved drugs sold as supplements or energy drinks, including the antidepressant tianeptine. Sometimes referred to collectively as 'gas station heroin,' the drugs have been restricted by several states, but they are not scheduled at the federal level. ___ The Associated Press Health and Science Department receives support from the Howard Hughes Medical Institute's Department of Science Education and the Robert Wood Johnson Foundation. The AP is solely responsible for all content.
Saudi Gazette
29-07-2025
- Saudi Gazette
Jamaican conjoined twins arrive in Riyadh for possible separation surgery
Saudi Gazette report RIYADH — The conjoined Jamaican twins, Azaria and Azura Elison, arrived Monday at King Khalid International Airport in Riyadh aboard a medical evacuation flight operated by the Saudi Ministry of Defense. Upon arrival, the twins were transferred to King Abdullah Specialist Children's Hospital at King Abdulaziz Medical City under the Ministry of National Guard for a comprehensive medical evaluation and to assess the feasibility of a separation surgery. The initiative comes in line with the directives of Custodian of the Two Holy Mosques King Salman bin Abdulaziz and Crown Prince and Prime Minister Mohammed bin Salman, reflecting Saudi Arabia's ongoing humanitarian commitment to complex pediatric cases around the world. Dr. Abdullah Al Rabeeah, Supervisor General of the King Salman Humanitarian Aid and Relief Center and head of the medical and surgical team for the Saudi Conjoined Twins Program, expressed deep gratitude to the Saudi leadership. He praised the Kingdom's advanced medical capabilities and humanitarian leadership in treating children with complex conditions noted that the Saudi medical team has built significant expertise over the years, having successfully performed numerous separation surgeries, making Saudi Arabia a global reference in this highly specialized twins' family expressed heartfelt appreciation to the Kingdom's leadership and people for their warm reception, generous hospitality, and swift response to the twins' condition.
